Cardiovascular Risk Management Recommendations for Patients with Chronic Myeloid Leukaemia who are Candidates for Ponatinib: Multidisciplinary Delphi Analysis

Ponatinib Ann Hematol 2021

Consenso con participación de socios de la SETH

  Artículo completo en PDF


Progress in the treatment of Chronic Myeloid Leukaemia (CML) has significantly improved the survival rates and prognosis of these patients. As a result, there is a growing awareness of the adverse effects that the treatments used can have on the Cardiovascular (CV) system. A high percentage of patients develop sequential resistance to CML treatments and, in these cases, ponatinib represents a good therapeutic option that has been associated with cardiovascular events. This required the development of recommendations for its management.

A Delphi analysis conducted by a multidisciplinary panel of experts developed and agreed on clinical practice recommendations to optimize cardiovascular risk control in CML patients requiring ponatinib treatment.


The aim of the study was to obtain feedback from members of a multidisciplinary panel of experts on best clinical practices to reduce the risk of cardiovascular events and inappropriate treatment interruptions in patients with CML treated with ponatinib.



Ver Publicaciones de socios SETH

Nuestra web utiliza cookies para ofrecerte un mejor servicio. Si continúas navegando, consideramos que aceptas su uso. Puedes visitar nuestro 'Uso de cookies' para obtener más información o cambiar tu configuración.